AI Summary
Quest Diagnostics will integrate its Haystack MRD ctDNA test and CGP tests into Flatiron Health's OncoEMR MPI, via a pilot with American Oncology Network and other community providers. The rollout will enable about 4,700 Flatiron clinicians across 1,600 sites to order Quest tests more easily, with a nationwide launch planned in H2 2026. This should boost Haystack MRD adoption and potential DGX revenue, while reducing clinician workflow friction.
Sentiment Rationale
The integration into OncoEMR MPI with Flatiron expands the addressable testing base and could drive higher Haystack MRD test volumes and related CGP services, supporting revenue growth and utilization of Quest's oncology test portfolio. The nationwide rollout in H2 2026 could accelerate this ramp, though adoption delays and payer coverage remain risks.
Trading Thesis
DGX upside potential from expanded Haystack MRD adoption through OncoEMR MPI pilot; watch H2 2026 rollout progress for revenue ramp timing.
Market-Moving
- Haystack MRD adoption could rise as OncoEMR MPI expands.
- OncoEMR MPI integration broadens Quest testing access across 4,700 Flatiron clinicians.
- H2 2026 nationwide rollout sets up potential revenue ramp for Quest.
- Pilot with AON signals broader market uptake in community oncology.
Key Facts
- Quest Diagnostics to integrate Haystack MRD and CGP in OncoEMR MPI.
- Pilot includes American Oncology Network and 4,700 Flatiron clinicians.
- Nationwide rollout planned for second half of 2026.
- Aims to simplify test ordering and accelerate oncology insights.
Companies Mentioned
- Quest Diagnostics (DGX): Expanding oncology test access via OncoEMR MPI pilot; potential lift to Haystack MRD usage.
- Flatiron Health (N/A): OncoEMR MPI integration; network of ~4,700 clinicians across ~1,600 sites; Roche affiliate.
- American Oncology Network (AON): Pilot partner; 350+ providers across 21 states; ~200 sites with OncoEMR MPI access.
Industry News
Industry News: highlights a strategic integration that could broaden DGX's Haystack MRD adoption through major community oncology networks and EHR workflows.